The Medical Letter on Drugs and Therapeutics
Bendamustine (Treanda) for CLL and NHL
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Correction: In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).

Bendamustine HCl (Treanda – Cephalon), an unusual DNA-alkylating agent that has been used in Europe for many years to treat lymphoma, has now been approved by the FDA for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).1,2

CLINICAL STUDIES — CLL – FDA approval of bendamustine for treatment of CLL was apparently based on a single unpublished study of 305 patients with previously untreated B-cell CLL randomized to IV bendamustine or oral chlorambucil (Leukeran). The overall response rate (ORR) was 68% and the complete response (CR) rate was 30% with bendamustine, compared to an ORR of 39% and CR of 2% with chlorambucil.3 Median progression-free survival was 21.7 months with bendamustine vs. 9.3 months with chlorambucil, and median duration of remission was 18.9 months for bendamustine and 6.1 months ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bendamustine (Treanda) for CLL and NHL
Article code: 1299c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian